Transplant International · 2004 · 48 citations · 31 references
PharmacyInfectious DiseasesPharmacotherapyHepatitis PharmacotherapyHepatologyTransplant PharmacotherapyAntiviral TherapyInterferon-based TherapyLiver DiseaseLiver TransplantationViral HepatitisViral Hepatitis TreatmentAdult Liver TransplantationHepatitis C ManagementHepatitis Treatment After Liver TransplantationLiver Transplantation ManagementRibavirin TherapyRibavirin-based RegimensViral Hepatitis Reactivation
Hepatitis C virus (HCV) infection invariably recurs after liver transplantation (LT), and sequels of chronic hepatitis of the graft are a significant cause of morbidity and mortality. In an uncontrolled trial, 31 patients with histologically confirmed hepatitis C after LT received, sequentially, ribavirin (10 mg/kg body weight q.d.) for 12 weeks, followed by ribavirin at the same dose q.d. plus interferon-alpha (IFN-alpha) [3 million units three times a week (3 MU TIW)] for another 48 weeks. Based on an intent-to-treat analysis, the percentages of patients with undetectable HCV RNA in their serum were 0%, 38.7% and 45.2% after 12, 36 and 60 weeks of therapy, respectively. A sustained virological response, as defined by undetectable serum HCV RNA 24 weeks after the end of treatment, was observed in 9/31 patients (29%). Sustained responders had a significant improvement of their liver inflammatory activity score (P=0.025), but not of their liver fibrosis score. The chances of sustained virological response correlated with the length of treatment, but not with the HCV genotype or baseline HCV RNA level. In conclusion, patients with recurrent hepatitis C after LT might benefit from ribavirin/IFN-alpha therapy, provided that the treatment is tolerated for a sufficient duration of time.
31
An Algorithm for the Grading of Activity in Chronic Hepatitis C
Pierre Bédossa, Thierry Poynard · Hepatology · 1996 · 4K citations · Full text
Thierry Poynard, Patrick Marcellin, Samuel S. Lee et al. · The Lancet · 1998 · 2.3K citations